Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: AMETEK, Thermo Fisher Scientific, IQVIA, Lowe's Companies and Alexion Pharmaceuticals

Read MoreHide Full Article

For Immediate Release

Chicago, IL – November 14, 2019 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AMETEK Inc. (AME - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) , IQVIA Holdings Inc. (IQV), Lowe's Companies Inc. (LOW - Free Report) and Alexion Pharmaceuticals Inc. (ALXN - Free Report) .

Here are highlights from Wednesday’s Analyst Blog:

5 Most-Loved S&P 500 Stocks on Wall Street

The S&P 500 has gained solid momentum to start the fourth quarter with the index hitting new all-time highs. In fact, the benchmark crossed the 3,100 level for the first time in intraday trading on Nov 12 thanks to renewed trade deal optimism, better-than-expected earnings and monetary easing policy that whet the risk appetite of investors.

The United States is expected to sign a phase one trade deal with China later this month. On the Q3 earnings front, of the 447 S&P members that have reported results, 72.5% companies beat EPS estimates and 57.9% beat on revenues. The proportion of these companies beating EPS and revenue estimates is in the historical range.

Major central banks across the globe are taking steps to prop up slowing economic growth that have eased global recession concerns and in turn lifted investors’ confidence. The Fed has slashed interest rates three times so far this year and the European Central Bank also cut interest rates in a package of easing measures.

Given the bullishness and record-high market, we have screened for five S&P 500 stocks that are most loved by the brokerage firms with the help of the Zacks Stock Screener. The parameters include a Zacks Rank #1 (Strong Buy) or 2 (Buy), VGM Score of A or B, highest percentage of buy ratings, estimated double-digit earnings growth for this year and a top-ranked Zacks industry. You can see the complete list of today’s Zacks #1 Rank stocks here.


Based in Berwyn, PA, AMETEK is one of the leading manufacturers of electronic appliances and electromechanical devices.

Zacks Rank: #2
VGM Score: B

Zacks Industry Rank: Top 10%
Fiscal 2019 Estimated earnings Growth: 25.5%
% of analysts with Strong Buy or Buy: 91.7%
YTD Return: 42.3%

Thermo Fisher Scientific Inc.

Based in Waltham, MA, Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science.

Zacks Rank: #2
VGM Score: B
Zacks Industry Rank: Top 33%
Fiscal 2019 Estimated earnings Growth: 10.8%
% of analysts with Strong Buy or Buy: 90%
YTD Return: 31.2%

IQVIA Holdings Inc.

Based in Durham, NC, IQVIA Holdings provides advanced analytics, technology solutions and contract research services to the life sciences industry.

Zacks Rank: #2
VGM Score: B
Zacks Industry Rank: Top 30%
Fiscal 2019 Estimated earnings Growth: 14.9%
% of analysts with Strong Buy or Buy: 84.6%
YTD Return: 21%

Lowe's Companies Inc.

Based in Mooresville, NC, Lowe’s Companies is one of the leading home improvement retailers, which has its operations primarily in the United States, Canada and Mexico.

Zacks Rank: #2
VGM Score: B
Zacks Industry Rank: Top 22%
Fiscal 2019 Estimated earnings Growth: 10.3%
% of analysts with Strong Buy or Buy: 82.6%
YTD Return: 23.9%

Alexion Pharmaceuticals Inc.

Based in New Haven, CT, Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life-transforming drugs, for the treatment of patients with ultra-rare disorders.

Zacks Rank: #2
VGM Score: A
Zacks Industry Rank: Top 22%
Fiscal 2019 Estimated earnings Growth: 30.4%
% of analysts with Strong Buy or Buy: 82.3%
YTD Return: 12%

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

 Media Contact

Zacks Investment Research

800-767-3771 ext. 9339                                                                            


Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit information about the performance numbers displayed in this press release.